MetrioPharm Announces Topline Data of its Phase IIa Study of MP1032 in COVID-19 Patients

MetrioPharm Announces Topline Data of its Phase IIa Study of MP1032 in COVID-19 Patients Orally administered MP1032 with very favorable safety and tolerability profile Compound equally effective as Remdesivir or Nirmatrelvir/Ritonavir as monotherapy Oral administration and suitability for early intervention address high unmet medical need   Zurich, December 8, 2022 – MetrioPharm AG, a pharmaceutical company […]

MetrioPharm’s MP1032 has anti-viral effects on different SARS-CoV-2 Variants of Concern

MetrioPharm’s MP1032 has anti-viral effects on different SARS-CoV-2 Variants of Concern By Dr. Christian Setz, Scientific Managing Director of ImmunoLogik This is the third article within our series of six covering different aspects of work behind the scenes in the iMPAct project. In today’s article, we will explore pre-clinical studies performed to test the efficacy of MetrioPharm’s […]

A regulatory strategy for the use of MP1032 in pediatric patients

A regulatory strategy for the use of MP1032 in pediatric patients By Dr. Volker Blust, Founder of PHOX Consulting e.U. This is the second article within our series of six covering different aspects of work behind the scenes in the iMPAct project. In today’s article, we explore the role of regulation within the drug development process. We […]

The Joint Meeting of DGfI & ÖGAI 2022

The Joint Meeting of DGFI & ÖGAI 2022 In September Sara Schumann attended the Joint Meeting of The DGFI Young Immunologists & ÖGAI 2022 where basic immunology met clinical immunology. At this conference, 250 lectures were held, 300 posters were presented, 50 exhibitors were present and almost 1000 participants attended. Find out more here: https://bit.ly/3TBmjvF Sara presented a poster on […]

An automated manufacturing process for MP1032 

An automated manufacturing process for MP1032 By Dr. Thies Klüßendorf, Senior Chemistry, Manufacturing, and Controls (CMC) Project Manager, MetrioPharm    This is the first article within our series of six covering various aspects of work behind the scenes in the iMPAct project. In today’s article, we explain what to consider when manufacturing MetrioPharm’s medicinal compound MP1032 and […]

Last Patient Out: MetrioPharm Completes Clinical Phase II Trial in COVID-19

Last Patient Out: MetrioPharm Completes Clinical Phase II Trial in COVID-19 The last patient had his/her last visit in MetrioPharm’s trial in COVID-19 on July 28tth Data cleaning and analysis will start subsequently Topline Data expected in Q4 2022   Zurich, July 29, 2022.  MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory diseases, announced […]

MetrioPharm partakes in EU-wide coordination and collaboration meeting for EU-funded projects conducting clinical trials on COVID-19 therapeutics

MetrioPharm partakes in EU-wide coordination and collaboration meeting for EU-funded projects conducting clinical trials on COVID-19 therapeutics Virtual meeting, April 06, 2022     We are two years into a novel coronavirus pandemic that affects and transforms countless lives worldwide. While considerable progress has taken place over these last years – such as the creation of […]

MetrioPharm surpasses 50% of enrollment in Phase II study in COVID-19  

MetrioPharm surpasses 50% of enrollment in Phase II study in COVID-19 Zurich, March 02, 2022.   MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory diseases, announced on the 2nd of March that more than 50% of the number of patients that were planned to be enclosed, have now been enrolled in the Phase II […]

MetrioPharm Signs European Commission Grant Agreement for €7.9 Million

MetrioPharm Signs European Commission Grant Agreement for €7.9 Million European commission funds COVID project iMPact with 7.9 million euros MetrioPharm will receive a total of 7.5 million euros of the provided sum iMPact project aims to research COVID-19 therapies   Zurich, November 24, 2021. MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory diseases, announces that […]